CAVADEXTRIN® reduces atherosclerosis
Heart disease and treatment explained.
Breakthrough Discovery reverses Heart Disease
In 2016 a team of scientists from Germany's Bonn University discovered
a new compound that reduced plaque in mice by over 40% in as little as 4 weeks.
The new cyclodextrin compound (CAVADEXTRIN®) was also tested on human plaque and they discovered it affected the plaque in a similar way.
After years of research, our RemChol tubes deliver 6 grams of CAVADEXTRIN® that circulates around the vascular system sucking up cholesterol and other lipids and transporting it out via the urinary system.
Angina dramatically reduced in 30 days. No diets or exercise.
Read the science
Cholrem is a world leader in the treatment of Heart Disease.
Start your treatment today
Remchol for home use
CAVADEXTRIN® can only be absorbed into the blood stream when administered as an IV or as an enema.
RemChol delivers CAVADEXTRIN® via an enema.
Each tube contains 8 grams of CAVADEXTRIN® with over 2 grams absorbed into the blood stream with every treatment.
Remchol tubes can be administered as often as twice a day.
Cool, thank you. The product totally works. My Dr. is astonished
Fantastic. I am experiencing great results. My feet were numb and the feeling has returned
Since starting RemChol, I no longer have any angina pain and indeed the heaviness/pressure in/on my chest has lessened
I was having angina pain in my left arm. Most of that pain has subsided. If my pain was a 4 (out of 5) before, it's now a 1 (out of 5)
I seem to be able to do more with little to no nitroglycerine, so this is why I think RemChol is reducing the narrowing in my arteries
Before RemChol I couldn't walk more than 25 metres without angina pain. I just ran a 100 metre sprint without any angina at all !
Our Trial Data
APRIL 2019 : CHOLREM PTY LTD LEADS THE WORLD IN RESEARCH
Angiogram: First patient has plaque reduction in just 4 weeks
CAVADEXTRIN® was administered to our first patient at our Melbourne clinic in April 2019 and within 4 weeks the plaque was reduced.
CAVADEXTRIN® circulates around the cardiovascular system removing built up cholesterol and plaque resulting in significant plaque reduction.
CAVADEXTRIN® is absorbed via intravenous application or as an enema only. If taken orally it is destroyed in the gut and has no effect.
Regular low doses of CAVADEXTRIN® can have a significant effect on plaque build up over time.
JULY 2021 : N® BENEFIT ON LIPIDS AND LIVER
Lipid levels halved.
Dramatic reduction in plaque within 4 weeks
12 grams of CAVADEXTRIN® was administered for 26 days over a 48 day period.
STUNNING RESULTS Lipids halved, Liver improves, Plaque reduced.
Cholesterol from 10.6 (409) down to 4.1 (159)
Triglycerides from 20.0 (1771) down to 4.6 (409)
LDL from 3.7 (143) down to 1.8 (69)
GGT from 102 down to 78
ALT from 65 down to 37
AST from 42 down to 25
Cyclodextrin has shown to extend lifespan by almost 10% in mice
Mice treated with CAVADEXTRIN® showed higher neurological scores than compared with the mice given saline only..
Mice on CAVADEXTRIN® lived 10% longer.
CAVADEXTRIN® clears the vascular system and can extend lifespan.
In 2014 at the University of Texas Southwest Medical Center, a study was conducted on the effects of Cyclodextrin administered to mice.
They studied the lifespan of mice treated systemically with either saline or Cyclodextrin at weekly
intervals starting at 49 days of age until death. In each case, half of the males and females were
given Cyclodextrin and the remaining mice received only saline.
During the study, the mice were graded on their neurological function. There were no gender related differences in the neurological scores. This score, which broadly measures neurological function, declines as the animal’s condition deteriorates.
It is clear that Cyclodextrin treated mice showed higher neurological scores than compared with the mice given saline only.
All the mice given saline only had died by 98 days whereas the majority of those receiving Cyclodextrin died in the week following. This shows an almost 10% improvement in lifespan.
The human trial of CAVADEXTRIN conducted by Cholrem has consistantly shown the scientific evidence proving the benefits of Cyclodextrin on mice also has similar benefits on humans. It would be fair to assume that based on the science, humans treated with CAVADEXTRIN would also experience a similar benefit of lifespan extention as the mice.
Cyclodextrin reprogrammed the cells in plaques, leading to increased transport of the dissolved cholesterol away from the plaques...
Cyclodextrin dissolves cholesterol crystals and reduces atherosclerotic plaques...
can actually solubilize cholesterol and dissolve the plaques...
Soaked up cholesterol and removed it...
Norwegian University of Science and Technology
have the potential in lowering deaths caused by atherosclerosis...
CAVADEXTRIN® removes plaque and cholesterol
plaque reduced in just 4 weeks
A recent study by the University Hospital in Bonn, Germany discovered that cyclodextrin melts away cholesterol crystals (the main cause of arterial plaque that clogs arteries) and reduced existing plaque within just 4 weeks. The cyclodextrin bound to and dissolved the cholesterol crystals from the plaque of mice, leading to transport of the dissolved cholesterol away from the plaques. The same effects were seen in human plaque samples treated with cyclodextrin.Article : Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming
Improve Liver function
Another study by the University of Texas Southwestern Medical Center, Dallas, Texas, shows the treatment of Npc1-deficient mice slows cholesterol sequestration in major organs and improves liver function. This study shows that cyclodextrin is effective in mobilizing entrapped cholesterol in late stage NPC disease leading to improved liver function.Article : Systemic administration of 2-hydroxypropyl-B-cyclodextrin to symptomatic Npc1-deficient mice slows cholesterol sequestration in the major organs and improves liver function.
Molecular mechanism of cyclodextrin mediated cholesterol extraction
Rationale for Therapeutic Use of Lipid Transport Mediators in Renal Disease
Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury.
Systemic and renal lipids in kidney disease development and progression
Metabolism, energetics, and lipid biology in the podocyte - cellular cholesterol-mediated glomerular injury.
Lipid biology of the podocyte--new perspectives offer new opportunities.
Renal lipid metabolism and lipotoxicity.
Cyclodextrins and Non-renal Diseases
Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming.
Weekly Treatment of 2-Hydroxypropyl-β-cyclodextrin Improves Intracellular Cholesterol Levels in LDL Receptor Knockout Mice.
Beta cyclodextrins bind, stabilize, and remove lipofuscin bisretinoids from retinal pigment epithelium.
Neuroprotection by cyclodextrin in cell and mouse models of Alzheimer disease.
Cyclodextrins and Renal Disease
Cyclodextrin Protects Podocytes in Focal Segmental Glomerulosclerosis (FSGS)
Hydroxypropyl-β-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis.
Cyclodextrin improves renal function in experimental alport syndrome.